MX370538B - Marcadores genéticos para la predicción de respuesta a la terápia. - Google Patents

Marcadores genéticos para la predicción de respuesta a la terápia.

Info

Publication number
MX370538B
MX370538B MX2015013505A MX2015013505A MX370538B MX 370538 B MX370538 B MX 370538B MX 2015013505 A MX2015013505 A MX 2015013505A MX 2015013505 A MX2015013505 A MX 2015013505A MX 370538 B MX370538 B MX 370538B
Authority
MX
Mexico
Prior art keywords
hdl
therapy
genetic markers
modulator
raising
Prior art date
Application number
MX2015013505A
Other languages
English (en)
Other versions
MX2015013505A (es
Inventor
Tardif Jean-Claude
Dubé Marie-Pierre
J Niesor Eric
Upmanyu Ruchi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015013505A publication Critical patent/MX2015013505A/es
Publication of MX370538B publication Critical patent/MX370538B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invención se refiere a métodos de genotipo y composiciones para seleccionar pacientes con enfermedad cardiovascular que se beneficiarán del tratamiento con un agente de elevación de HDL o que imita HDL, en particular con un inhibidor/modulador de CETP.
MX2015013505A 2013-03-27 2014-03-24 Marcadores genéticos para la predicción de respuesta a la terápia. MX370538B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13161386 2013-03-27
PCT/EP2014/055790 WO2014154606A1 (en) 2013-03-27 2014-03-24 Genetic markers for predicting responsiveness to therapy

Publications (2)

Publication Number Publication Date
MX2015013505A MX2015013505A (es) 2016-01-14
MX370538B true MX370538B (es) 2019-12-17

Family

ID=47997187

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013505A MX370538B (es) 2013-03-27 2014-03-24 Marcadores genéticos para la predicción de respuesta a la terápia.
MX2019015058A MX2019015058A (es) 2013-03-27 2015-09-22 Marcadores geneticos para la prediccion de respuesta a la terapia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019015058A MX2019015058A (es) 2013-03-27 2015-09-22 Marcadores geneticos para la prediccion de respuesta a la terapia.

Country Status (20)

Country Link
US (4) US9909178B2 (es)
EP (2) EP2978859B1 (es)
JP (2) JP6449235B2 (es)
KR (1) KR102153557B1 (es)
CN (2) CN111073974B (es)
BR (1) BR112015024116A2 (es)
CA (1) CA2897420C (es)
DK (1) DK2978859T3 (es)
ES (1) ES2685269T3 (es)
HK (1) HK1213602A1 (es)
HR (1) HRP20181358T1 (es)
HU (1) HUE039973T2 (es)
LT (1) LT2978859T (es)
MX (2) MX370538B (es)
PL (1) PL2978859T3 (es)
PT (1) PT2978859T (es)
RS (1) RS57640B1 (es)
RU (1) RU2707533C2 (es)
SI (1) SI2978859T1 (es)
WO (1) WO2014154606A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
CA3146333A1 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
CN111073974B (zh) 2013-03-27 2024-04-09 豪夫迈·罗氏有限公司 用于预测对于治疗的响应性的遗传标记
MX2017000582A (es) * 2014-07-30 2017-04-27 Hoffmann La Roche Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).
WO2016147053A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US20190070178A1 (en) 2017-08-29 2019-03-07 Dalcor Pharma Uk Ltd., Stockport Zug Branch Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
CN108004312B (zh) * 2017-12-20 2019-01-01 德诺杰亿（北京）生物科技有限公司 检测心血管疾病相关基因多态性的引物组、试剂盒及方法
BR112021002387A2 (pt) * 2018-08-09 2021-05-11 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch métodos para retardo de ocorrência de diabetes tipo 2 de início recente e para redução da progressão e tratamento de diabetes tipo 2
WO2020178443A1 (en) 2019-03-07 2020-09-10 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing heart failure and reducing risk of heart failure
WO2021140358A1 (en) * 2020-01-08 2021-07-15 Universitatea De Medicina Şi Farmacie "Victor Babes" (In English: University Of Medicine And Pharmacy "Victor Babes") Method to identify patients who would respond favourably to hypolipidemic treatment

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
EP1185160B1 (en) 1999-06-04 2006-08-23 Consejo Superior de Investigaciones Cientificas High oleic and high stearic acid sunflower plants, seeds and oils
US20030092647A1 (en) 2001-08-08 2003-05-15 Crooke Rosanne M. Antisense modulation of cholesteryl ester transfer protein expression
US20030138444A1 (en) 2001-08-18 2003-07-24 Myriad Genetics, Incorporated Composition and method for treating HIV infection
WO2004067763A2 (en) * 2003-01-27 2004-08-12 The Regents Of The University Of Colorado, A Body Corporate Genetic diagnosis of alcoholism subtypes
MXPA05009976A (es) 2003-03-17 2005-11-04 Japan Tobacco Inc Metodo para incrementar la biodisponibilidad oral del 2-metilpropantioato de s-[2-([[1- 2-etilbutil) ciclohexil] carbonil] amino) fenilo].
TWI393560B (zh) 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
CA2554982A1 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1697370B1 (en) 2003-12-19 2007-04-25 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
JP2007514770A (ja) 2003-12-19 2007-06-07 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイド受容体モジュレーターとしてのアザビシクロ複素環
US20050261201A1 (en) 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
US7375112B2 (en) 2005-01-05 2008-05-20 Medicure International Inc. Compounds and methods for regulating triglyceride levels
WO2006099142A2 (en) * 2005-03-10 2006-09-21 The Trustees Of Boston University Prognostic method for vascular diseases
JP2006288279A (ja) * 2005-04-11 2006-10-26 Otsuka Pharmaceut Co Ltd 出血時間延長傾向判定方法
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
US7435849B2 (en) 2005-10-31 2008-10-14 Hoffmann-La Roche Inc. Process for the production of acid chlorides
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US20070213274A1 (en) * 2005-12-20 2007-09-13 Oy Jurilab Ltd Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C)
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
EP1935867A1 (en) 2006-12-20 2008-06-25 F. Hoffmann-La Roche Ag Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
US20080221161A1 (en) 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
ES2395167T3 (es) 2007-04-25 2013-02-08 F. Hoffmann-La Roche Ag Nuevo proceso para la obtención de cloruros de ácido
WO2009026241A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5
US20090054304A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
BRPI0911170B1 (pt) 2008-04-04 2018-05-29 F. Hoffmann-La Roche Ag Processo para a preparação de derivados do ácido ciclo-hexanocarboxílico via o correpondente derivado de ciclo-hexanocarboxamida
JP5564487B2 (ja) 2008-04-04 2014-07-30 エフ．ホフマン−ラ ロシュ アーゲー シクロヘキサンカルボン酸誘導体の新規な製造方法
JP5325980B2 (ja) 2008-06-17 2013-10-23 エフ．ホフマン−ラ ロシュ アーゲー 薬学的に活性なアミドの製造における中間体としての１−（２−エチル−ブチル）−シクロヘキサンカルボン酸エステル
EP2177615A1 (en) * 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
US20100183598A1 (en) 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
JP5538423B2 (ja) 2008-12-08 2014-07-02 エフ．ホフマン−ラ ロシュ アーゲー 薬物の併用投与
NZ789295A (en) 2009-04-29 2024-02-23 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20110004011A1 (en) 2009-07-01 2011-01-06 Declan Costello Novel process
WO2011008996A2 (en) 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable
WO2012012870A1 (en) 2010-07-28 2012-02-02 Institut De Cardiologie De Montreal Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
EP2616433B1 (en) 2010-09-16 2015-12-09 F.Hoffmann-La Roche Ag Process for preparing a cyclohexanecarbonitrile derivative
NZ609529A (en) 2010-11-04 2015-06-26 Hoffmann La Roche A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
CA2818018C (en) 2010-12-08 2016-02-02 F. Hoffmann-La Roche Ag Liposomal formulation of dalcetrapib
TR201818880T4 (tr) 2010-12-16 2019-01-21 Hoffmann La Roche Disülfürlerin hidrojenasyonu yoluyla aromatik tiyol türevlerinin hazırlanması prosesi.
WO2012112720A2 (en) * 2011-02-15 2012-08-23 The Ohio University Research Foundaton Methods for predicting cardiovascular risks and responsiveness to statin therapy using snps
KR20140006879A (ko) * 2011-02-17 2014-01-16 에프. 호프만-라 로슈 아게 고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
EP2694981A1 (en) 2011-04-08 2014-02-12 Zora Biosciences OY Biomarkers for sensitive detection of statin-induced muscle toxicity
US20120301439A1 (en) 2011-05-24 2012-11-29 Washington University Inhibition of choroidal neovascularization
US8975438B2 (en) 2011-07-13 2015-03-10 Hoffmann-La Roche Inc. Process for the preparation of cyclohexanecarboxylic acid derivatives
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
US9662339B2 (en) 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
CN104244946A (zh) 2012-04-30 2014-12-24 霍夫曼-拉罗奇有限公司 新制剂
MX351059B (es) 2012-08-17 2017-09-29 Laboratorios Senosiain S A De C V Star Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
CN111073974B (zh) * 2013-03-27 2024-04-09 豪夫迈·罗氏有限公司 用于预测对于治疗的响应性的遗传标记
MX2016005505A (es) 2013-12-19 2016-07-22 Hoffmann La Roche Modulador de la proteina de transferencia de ester de colesterilo (cetp) para usarse en el tratamiento de enfermedades oculares.
MX2017000582A (es) * 2014-07-30 2017-04-27 Hoffmann La Roche Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).
US20190070178A1 (en) * 2017-08-29 2019-03-07 Dalcor Pharma Uk Ltd., Stockport Zug Branch Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
BR112021002387A2 (pt) 2018-08-09 2021-05-11 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch métodos para retardo de ocorrência de diabetes tipo 2 de início recente e para redução da progressão e tratamento de diabetes tipo 2

Also Published As

Publication number Publication date
US20190226020A1 (en) 2019-07-25
RU2019123202A (ru) 2019-12-10
DK2978859T3 (en) 2018-09-03
RU2707533C2 (ru) 2019-11-27
MX2015013505A (es) 2016-01-14
HUE039973T2 (hu) 2019-02-28
ES2685269T3 (es) 2018-10-08
RS57640B1 (sr) 2018-11-30
MX2019015058A (es) 2020-02-13
CA2897420C (en) 2020-10-27
SI2978859T1 (sl) 2018-10-30
WO2014154606A1 (en) 2014-10-02
US20180155784A1 (en) 2018-06-07
JP6449235B2 (ja) 2019-01-09
US10711303B2 (en) 2020-07-14
RU2015145133A (ru) 2017-05-04
EP3404115A1 (en) 2018-11-21
EP2978859B1 (en) 2018-06-27
CN105164276B (zh) 2020-01-14
HRP20181358T1 (hr) 2018-10-19
JP2016515824A (ja) 2016-06-02
US20160244826A1 (en) 2016-08-25
CA2897420A1 (en) 2014-10-02
US20210017597A1 (en) 2021-01-21
CN111073974A (zh) 2020-04-28
CN105164276A (zh) 2015-12-16
BR112015024116A2 (pt) 2017-10-24
JP2019058180A (ja) 2019-04-18
PL2978859T3 (pl) 2018-10-31
EP2978859A1 (en) 2016-02-03
KR20150134342A (ko) 2015-12-01
PT2978859T (pt) 2018-10-04
US9909178B2 (en) 2018-03-06
KR102153557B1 (ko) 2020-09-09
CN111073974B (zh) 2024-04-09
US11549142B2 (en) 2023-01-10
HK1213602A1 (zh) 2016-07-08
LT2978859T (lt) 2018-09-10

Similar Documents

Publication Publication Date Title
MX2019015058A (es) Marcadores geneticos para la prediccion de respuesta a la terapia.
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
MX2021006626A (es) Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).
ZA201701845B (en) Galnac phosphoramidites, nucleic acid conjugates thereof and their use
IL290633A (en) 5'-cyclophosphonate modified nucleotides, preparations containing them and their uses
EP3653048C0 (en) METHODS AND COMPOSITIONS FOR TARGETING GENETIC MODIFICATION BY SINGLE-STEP MULTIPLE TARGETING
MY172180A (en) Impact-resistant pmma with improved optical properties
EP2971280A4 (en) BIOSENSOR MICROARRAY COMPOSITIONS AND METHOD
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
EP2998416A4 (en) HIGH YOUNG HIGH YOUNG MODULE STEEL SHEET, AND METHOD FOR MANUFACTURING THE SAME
SI3463457T1 (sl) Blokada pd-1 z nivolumabom pri refraktornem hodgkinovem limfomu
MA39495A (fr) Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
EP2998415A4 (en) HIGH YOUNG HIGH YOUNG MODULE STEEL SHEET AND METHOD FOR MANUFACTURING THE SAME
HK1221973A1 (zh) 甲基 丙烯酸類共聚物、樹脂組合物及其成型體
MX2017003793A (es) Material para moldeo resistente al impacto que tiene un perfil de caracteristicas mejorado.
HK1223610A1 (zh) 取代的 -三嗪- -二酮及其作為類糜蛋白酶抑制劑的用途
IN2014DN11078A (es)
SG10201802865PA (en) Sirna and their use in methods and compositions for inhibiting the expression of the orai1 gene
MX2016011688A (es) Composicion de resina de cloruro de vinilo, producto moldeado de resina de cloruro de vinilo, y laminado.
MY183119A (en) Vinyl ester powder pre-preg
Linckelmann ON STABLE AND DERIVED EQUIVALENCES OF BLOCKS AND ALGEBRAS.
IL257524B1 (en) Short interfering RNA and its use in methods and preparations for inhibiting the expression of ankyrin horseradish protein gene regulated by Nutz
EA201790642A1 (ru) Аллель-специфическая терапия для гаплотипов болезни хантингтона
Rutte Psychoanalytic Inquiry by Parlow, Susan B.

Legal Events

Date Code Title Description
FG Grant or registration